Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The concern about ACE/ARB and COVID-19: Time to hold your horses!

Joseph V. Pergolizzi Jr., MD, Giustino Varrassi, MD, Peter Magnusson, MD, Jo Ann LeQuang, BA *, Marianna Leopoulou, MD, Antonella Paladini, MD, Robert Taylor, PhD, Charles Wollmuth, MS, Frank Breve, PharmD, for the NEMA Research Group

ARTICLE INFO

Article history:
Received 7 April 2020
Accepted 30 June 2020
Available online 31 July 2020

ABSTRACT

Concern about coronavirus 2019 (COVID-19) morbidity and mortality has drawn attention to the potential role of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) because the SARS-CoV-2 uses the ACE2 receptor as its point of entry into the body. It is not clear if and to what degree the SARS-CoV-2 virus affects the renin-angiotensin system. Early studies from China which speculated on the role of ACE inhibition and ARBs did not evaluate the drug regimens. A vast body of evidence supports the use of ACE inhibitors and ARBs in hypertensive patients and patients with heart failure, and very little evidence has been acquired about their role in COVID-19. There is good evidence in support of the use of ACE inhibitors and ARBs in indicated patients with hypertension and heart failure, and clinicians should be reticent about abruptly withdrawing these drugs based on a paucity of evidence.

Early observations from the ongoing pandemic reveal that patients with cardiovascular risk factors are at elevated risk of adverse outcomes. Based on theoretical models of the renin-angiotensin system (RAS), and its suspected interaction with the novel coronavirus, suspicions have arisen about the use of certain pharmacologic agents during the coronavirus 2019 (COVID-19). This paper explains what is known about the pathophysiological mechanisms and provides a statement with respect to their clinical management.

The angiotensin-converting enzyme 2 (ACE2) has been identified as the receptor for the severe acute respiratory syndrome (SARS) coronavirus, and it appears likely that it is also the receptor for the novel SARS-CoV-2 virus associated with the COVID-19 pandemic. The ACE2 receptors bind to the spikes on the coronavirus and support syncitia as the virus injects its RNA to hijack the cell. A murine study found that ACE2-knockout mice are SARS resistant. Indeed, the ACE2 receptor appears crucial to SARS infection in vivo. It is presumed that the ACE2 receptor functions in similar fashion with the COVID-19 virus, but this remains unproven.

In addition to high expression in the epithelial cells of the lungs, intestines, kidneys, and blood vessels, a recent study also found a high expression of ACE2 receptors in the epithelial cells of the mucosal cells of the oral cavity. An intriguing commentary by Fang et al. suggested that based on early data from Chinese patients, those with hypertension, diabetes, or both might be at elevated risk for COVID-19 infection. However, none of the earlier studies and reports published by the Chinese colleagues evaluated the pharmacologic regimens of the patients. The hasty response against specific drugs in the setting of COVID-19 has been effectively challenged as being speculative rather than evidence based.

Results from several Chinese reports are summarized in Table 1. None of these studies described drug regimens of these patients. A study from Korea (n = 28) found that 36% of the confirmed COVID-19 patients in the study had at least one underlying disease including hypertension, diabetes, asthma, chronic rhinitis, dyslipidemia, or hypothyroidism; one patient in this study had been treated for lung cancer. A meta-analysis of COVID-19 in China (n = 1527 patients, 6 studies) reported that of the hospitalized patients, 17.1% had...
Key Points

Background:

- Early studies from China implicated angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers as being potentially of risk in coronavirus 2019 patients, but this evidence is not based on actual drug use patterns.

Findings:

- ACE inhibitors and angiotensin-receptor blockers are important drugs for the treatment of hypertension and heart failure, and a vast amount of evidence supports their use; they should not be abruptly withdrawn based on a paucity of evidence.
- The SARS-CoV-2 virus enters the body through the ACE2 receptor.

Concern about ACE/ARB and COVID-19

hypertension, 16.4% had cardiac or cerebrovascular disease, and 9.7% had diabetes, but the rates were 2- to 3-fold greater among COVID-19 patients in the intensive care.9

None of these studies specifically evaluated the use of ACE inhibitors or other medications in COVID-19 patients, but the speculation is that patients with such comorbidities would often be treated with ACE inhibitors. Fang et al.,6 then proposed that ACE inhibition upregulates ACE2, which, in turn, would facilitate COVID-19 infection. This has focused attention on the role of the RAS in the context of coronavirus.

RAS, which maintains blood pressure homeostasis, is an enzymatic cascade that uses renin produced by the kidneys to transform angiotensinogen (Ang) into Angl. Angl is catalyzed by ACE enzyme to produce AngII, which is catalyzed by the ACE2 into Ang1-7 and Ang1-9.15,16 While AngI is physiologically inactive, AngII, catalyzed by the ACE enzyme, is a vasoconstrictor and regulates aldosterone secretion.16 Pharmacologic inhibition of the ACE enzyme using drugs such as captopril, enalapril, lisinopril, or other ACE inhibitors, are frequently used to treat hypertension and heart failure.16 It should be noted that in the conversion of AngI into AngII, the ACE enzyme inactivates the vasodilating peptides bradykinin and kallidin.17

The ACE2 enzyme was first discovered in 2000 and remains to be more fully elucidated. There are distinct differences between ACE and ACE2, the 2 key enzymes of the RAS. ACE is a dipeptidyl carboxypeptidase while ACE2 is a carboxypeptidase. ACE2 appears to be a chimeric protein.18 ACE2 cleaves only a single C-terminial residue from the peptide substrate and cannot cleave to bradykinin or other ACE substrates; ACE2 does not appear to be susceptible to pharmacologic ACE inhibition.19 Because ACE2 is a type I transmembrane protein with a large catalytic extracellular domain, it can act as a peptidase or viral receptor. Its extracellular domain can be cleaved from the cell surface by other peptidases and the enzymatic activity on the cell surface may be modulated by S-protein binding and clustering in "lipid rafts" or microdomains.20 A murine study found that pharmacologic ACE inhibition upregulated ACE2 in rats with hepatic fibrosis, both in vivo and in vitro.21

ACE enzymes are abundant and widely distributed in the body. At first, it was believed that ACE2 enzymes were found only or mainly in the heart, kidney, and testes,22 but it appears they are also found in the intestines, epithelia of the lungs, and oral mucosa.5,23,24 In fact ACE2 may be far more abundant in the body than originally thought. The ACE2 enzyme is thought to play a role in cardiac function, the endocrine system, and blood pressure.25

As ACE2 was only recently discovered and much remains unknown about the angiotensin enzymatic cascade, it is not immediately clear how the novel SARS-CoV-2 virus might affect RAS, if indeed ACE2 is its viral receptor. Further questions arise, such as the potential role of ACE2 polymorphisms in the context of COVID-19 and other emerging coronaviruses. Are some people genetically predisposed to a more severe form of infection? If this is the case, it could possibly explain the patterns of COVID-19 outbreaks. Would other emerging coronaviruses also use ACE2 as the viral receptor? This makes it crucial to gain a better understanding of ACE2, RAS, and viral infections. Another key question is whether or not pharmacologic ACE inhibition, which increases ACE2 in the body, might either increase a person’s risk of contracting COVID-19 or, alternately, exacerbate COVID-19 infection once it occurs. Such knowledge has life-saving ramifications in that hypertension, ischemic cardiac disease, and heart failure are prevalent conditions often treated with ACE inhibitors.

In these challenging days of trying to manage acute cases of COVID-19 infection, it is important to focus our future attention on greater understanding of the coronavirus infection and its interactions with RAS. Coronavirus infections, including SARS, Middle Eastern Respiratory Disease, H1N1, and others have emerged in the recent years, and there is no reason to

Table 1
Emerging studies on patients with severe COVID-19 and the rates of diabetes, hypertension, and cerebrovascular disease

| Study | Diabetes (%) | Hypertension (%) | Cerebrovascular disease (%) |
|-------|--------------|------------------|----------------------------|
| Yang et al. 202012 | 22 | Not stated | 22 |
| 32 nonsurvivors from a cohort of 52 intensive-care patients |
| Guan et al. 200211 | 16.2 | 23.7 | 2.3 |
| 173 patients with severe disease from a study of 1099 patients |
| Zhang et al. 202012 | 12 | 30 | Not stated |
| 140 hospitalized patients |
| Deng et al. 202013 | 42 | 54 | 15 |
| 26 fatal cases |
| Wu et al. 202014 | 19.0 | 27.4 | Not stated |
| 201 patients who developed acute respiratory distress syndrome or died |

Abbreviation used: COVID-19, coronavirus 2019.
think that this is the final novel coronavirus to break the species barrier and infect humans. It is likely (but not known) that emerging coronaviruses will affect ACE2 and RAS, which is crucial to blood pressure homeostasis and respiratory health. Research is urgently needed and should be generously funded to avert potential future—and economically devastating—pandemics.

**Clinical perspective**

The social—media-driven amplification of concerns about ACE inhibitors and angiotensin-receptor blockers (ARBs) in the current pandemic are based on speculations about mechanisms that have not been elucidated. In fact, some patients have stopped taking their prescribed medications in the light of this news. For that reason, it is crucial that it be stated that while there is no evidence that supports the interaction between the RAS and the SARS-CoV-2 virus, there is abundant scientific evidence and clinical experience supporting the fact that ACE or ARB treatment is beneficial to people with cardiovascular risk factors. Indeed, preexisting heart failure is likely to worsen with COVID-19 and myocarditis with reduced ejection fraction has been reported, so it is of utmost importance to continue the ACE or ARB regimen. Based on current knowledge, there is no reason to discontinue these important drugs, which are a cornerstone of modern cardiology. Please, colleagues, hold your horses! Patients who express concern about ACE inhibitors or ARBs should be reassured that these drugs are and remain important even during this pandemic, based on the best available scientific evidence. These drugs should not be withdrawn on this unscientific speculation. In this and many other matters, science and evidence will save lives.

**References**

1. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003;426(6965):450–454.

2. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J Virol*. 2020;94(7):e00127–2.

3. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med*. 2005;11(8):875–879.

4. Kuba K, Imai Y, Rao S, Jiang C, Penninger JM. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. *J Mol. Med*. 2006;84(10):814–820.

5. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci*. 2020;12(1):8.

6. Fang L, Karakulaklis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med*. 2020;8(4):e21.

7. Varrasi C. Warning against the use of anti-inflammatory medicines to cure COVID-19: building castles in the air. *Adv Ther*. 2020;37(5):1705–1707.

8. COVID-19 National Emergency Response Center. Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea. *Osong Public Health Res Perspect*. 2020;11(1):1–14.

9. Li B, Yang L, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin Res Cardiol Off J Ger Card Soc*. 2020;109(5):531–538.

10. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med*. 2020;8(5):475–481.

11. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–1720.

12. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China [e-pub ahead of print]. *Allergy*. 2020. https://doi.org/10.1111/all.14238, accessed March 27, 2020.

13. Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus Disease 2019 outbreak in. *Chin J Clin Med*. 2020;9(2):375.

14. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus Disease 2019 pneumonia in Wuhan, China [e-pub ahead of print]. *JAMA Intern Med*. 2020. https://doi.org/10.1001/jamainternmed.2020.0994, accessed March 27, 2020.

15. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. *Trends Pharmacol Sci*. 2002;23(4):177–183.

16. Tamimoto K, Sugiyama F, Goto Y, et al. Angiotensinogen-deficient mice with hypotension. *J Biol Chem*. 1994;269(50):31334–31337.

17. Boehm M, Nabel EG. Angiotensin-converting enzyme 2—a new cardiac regulator. *N Engl J Med*. 2002;347(22):1795–1797.

18. Danilczyk U, Sarao R, Remy C, et al. Essential role for collectrin in renal amino acid transport. *Nature*. 2006;444(7122):1088–1091.

19. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoril-insensitive carboxypeptidase. *J Biol Chem*. 2000;275(43):33238–33243.

20. Lambert DW. The cell biology of the SARS coronavirus receptor, angiotensin-converting Enzyme 2. In: Lal SK, ed. Molecular Biology of the SARS-CoV. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010:23–30.

21. Huang ML, Li X, Meng Y, et al. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors. *Clin Exp Pharmacol Physiol*. 2010;37(1):e16–e6.

22. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. *Circ Res*. 2000;87(5):e1–e9.

23. Hooper NM, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoril-insensitive carboxypeptidase. *J Biol Chem*. 2000;275(43):33238–33243.

24. Guy J, Lambert DW, Warner FJ, Hooper NM, Turner AJ. Membrane-associated zinc peptidase families: comparing ACE and ACE2. *Biochim. Biophys. Acta*. 2005;1715(1):1–2.

25. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and cellular perspective. *Cell Mol Life Sci*. 2006;64(21):2704–2713.

Joseph V. Pergolizzi, Jr, MD, Chief Operating Officer, NEMA Research, Inc., Naples, FL

Giustino Varrasi, MD, President, Paolo Procacci Foundation, Rome, Italy; President, World Institute of Pain, Winston-Salem, NC

Peter Magnusson, MD, Centre for Research and Development, Uppsala/ Gavleborg County, Gavle, Sweden; Department of Medicine, Cardiology Research Unit, Karolinska Institutet, Stockholm, Sweden

Jo Ann LeQuang, BA, Director of Scientific Communications, NEMA Research Inc., Naples, FL

Mariana Leopoulou, MD, Cardiology Resident, Cardiology Department, Athens General Hospital ‘Elpis’, Athens, Greece

Antonella Paladini, MD, Assistant Professor of Anesthesiology and Pain Medicine, Department MESVA, University of L’Aquila, Italy

Robert Taylor, PhD, Executive Director of Operations, NEMA Research Inc., Naples, FL

Charles Wollmuth, MS, Research Associate, NEMA Research Inc., Naples, FL

Frank Breve, PharmD, NEMA Research Inc., Naples, FL; Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA